相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutant Huntingtin is Present in Neuronal Grafts in Huntington Disease Patients
Francesca Cicchetti et al.
ANNALS OF NEUROLOGY (2014)
Multisource Ascertainment of Huntington Disease in Canada: Prevalence and Population at Risk
Emily R. Fisher et al.
MOVEMENT DISORDERS (2014)
Huntington disease: natural history, biomarkers and prospects for therapeutics
Christopher A. Ross et al.
NATURE REVIEWS NEUROLOGY (2014)
Role of Dopamine D2 Receptors in Human Reinforcement Learning
Christoph Eisenegger et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records
Stephen J. W. Evans et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor
K. Sahlholm et al.
MOLECULAR PSYCHIATRY (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
Clinical Neurogenetics Huntington Disease
Yvette M. Bordelon
NEUROLOGIC CLINICS (2013)
Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease
Nandakumar S. Narayanan et al.
REVIEWS IN THE NEUROSCIENCES (2013)
Motor function and dopamine release measurements in transgenic Huntington's disease model rats
Andrea N. Ortiz et al.
BRAIN RESEARCH (2012)
Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature
Jack J. Chen et al.
CLINICAL THERAPEUTICS (2012)
Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice
Mahmoud A. Pouladi et al.
HUMAN MOLECULAR GENETICS (2012)
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J. Tabrizi et al.
LANCET NEUROLOGY (2012)
Extrastriatal Dopamine D2 Receptor Binding in Huntington's Disease
Mouna Esmaeilzadeh et al.
HUMAN BRAIN MAPPING (2011)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Justo Garcia de Yebenes et al.
LANCET NEUROLOGY (2011)
Huntington's Disease: Can Mice Lead the Way to Treatment?
Zachary R. Crook et al.
NEURON (2011)
Impaired dopamine release and uptake in R6/1 Huntington's disease model mice
Andrea N. Ortiz et al.
NEUROSCIENCE LETTERS (2011)
Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea
Catherine Bedard et al.
PARKINSONISM & RELATED DISORDERS (2011)
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
Jean-Martin Beaulieu et al.
PHARMACOLOGICAL REVIEWS (2011)
In vivo dopamine efflux is decreased in striatum of both fragment (R6/2) and full-length (YAC128) transgenic mouse models of Huntington's disease
Joshua W. Callahan et al.
FRONTIERS IN SYSTEMS NEUROSCIENCE (2011)
Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
Anders Lundin et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal
Yasufumi Shirasaki et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
In vivo pharmacology of the dopaminergic stabilizer pridopidine
Henrik Ponten et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Synthesis and Evaluation of a Set of 4-Phenylpiperidines and 4-Phenylpiperazines as D2 Receptor Ligands and the Discovery of the Dopaminergic Stabilizer 4[3-(Methylsulfonyl)phenyl]-1-propylpiperidine (Huntexil, Pridopidine, ACR16)
Fredrik Pettersson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease
Marta Martinez-Vicente et al.
NATURE NEUROSCIENCE (2010)
Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers
Nicola Pavese et al.
NEUROBIOLOGY OF DISEASE (2010)
The Neural Circuitry of Executive Functions in Healthy Subjects and Parkinson's Disease
Sandra E. Leh et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
Samuel Frank
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2010)
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium
Benjamin Ray Miller et al.
FUTURE NEUROLOGY (2010)
Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
Samuel Frank
BMC NEUROLOGY (2009)
Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease
J. C. H. van Oostrom et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Emerging drug therapies in Huntington's disease
Sarah L. Mason et al.
EXPERT OPINION ON EMERGING DRUGS (2009)
Treatment of the Symptoms of Huntington's Disease: Preliminary Results Comparing Aripiprazole and Tetrabenazine
Livia Brusa et al.
MOVEMENT DISORDERS (2009)
Hypothalamic involvement in Huntingtons disease: an in vivo PET study
Marios Politis et al.
BRAIN (2008)
Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation
Anna Wade et al.
BRAIN RESEARCH (2008)
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
Samuel Frank et al.
CLINICAL NEUROPHARMACOLOGY (2008)
The Long-term Effect of Tetrabenazine in the Management of Huntington Disease
Alfonso Fasano et al.
CLINICAL NEUROPHARMACOLOGY (2008)
Mechanisms of neurodegeneration in Huntington's disease
Joana M. Gil et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II
Alexandra Benchoua et al.
HUMAN MOLECULAR GENETICS (2008)
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
Maria Bjorkqvist et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Detection of Huntington's disease decades before diagnosis: the Predict-HD study
J. S. Paulsen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice
Michelle Gray et al.
JOURNAL OF NEUROSCIENCE (2008)
How dopamine dysregulation leads to psychotic symptoms? Abnormal mesolimbic and mesostriatal prediction error signalling in psychosis
G K Murray et al.
MOLECULAR PSYCHIATRY (2008)
A Europe-Wide assessment of current medication choices in Huntington's disease
Josef Priller et al.
MOVEMENT DISORDERS (2008)
Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo
Delphine Charvin et al.
NEUROBIOLOGY OF DISEASE (2008)
Dopaminergic signaling and striatal neurodegeneration in Huntington's disease
Tie-Shan Tang et al.
JOURNAL OF NEUROSCIENCE (2007)
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons
D. James Surmeier et al.
TRENDS IN NEUROSCIENCES (2007)
Short-term effects of tetrabenazine on chorea associated with Huntington's disease
Christopher Kenney et al.
MOVEMENT DISORDERS (2007)
Animal models of Huntington's disease
Shilpa Ramaswamy et al.
ILAR JOURNAL (2007)
Mesocortical dopamine modulation of executive functions: beyond working memory
Stan B. Floresco et al.
PSYCHOPHARMACOLOGY (2006)
A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance
Paolo Calabresi et al.
LANCET NEUROLOGY (2006)
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat
Sridhar Natesan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits
R Levy et al.
CEREBRAL CORTEX (2006)
Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease
MA Johnson et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Chemistry of the mind: Neurochemical modulation of prefrontal cortical function
TW Robbins
JOURNAL OF COMPARATIVE NEUROLOGY (2005)
Unraveling a role for dopamine in Huntington's disease:: The dual role of reactive oxygen species and D2 receptor stimulation
D Charvin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease
TS Tang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The neurobiology of dopamine signaling
JA Girault et al.
ARCHIVES OF NEUROLOGY (2004)
Schizophrenia: From dopamine to glutamate and back
ML Carlsson et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation
C Wersinger et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2004)
Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology
GJ Yohrling et al.
MOLECULAR BRAIN RESEARCH (2003)
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons
M Cyr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology
DA Shapiro et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
EJ Slow et al.
HUMAN MOLECULAR GENETICS (2003)
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study
N Pavese et al.
BRAIN (2003)
Tetrabenazine treatment for Huntington's disease - Associated chorea
WG Ondo et al.
CLINICAL NEUROPHARMACOLOGY (2002)
Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice
Å Petersén et al.
NEUROBIOLOGY OF DISEASE (2002)
Olanzapine for Huntington's disease: An open label study
RM Bonelli et al.
CLINICAL NEUROPHARMACOLOGY (2002)
Olanzapine in Huntington's disease
D Paleacu et al.
ACTA NEUROLOGICA SCANDINAVICA (2002)
The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease
MA Hickey et al.
JOURNAL OF NEUROCHEMISTRY (2002)
High-dose olanzapine in Huntington's disease
RM Bonelli et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2002)
Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers
M Suzuki et al.
SYNAPSE (2001)
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
C Zuccato et al.
SCIENCE (2001)
Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration
Å Petersén et al.
HUMAN MOLECULAR GENETICS (2001)
Decreased striatal monoaminergic terminals in Huntington disease
NI Bohnen et al.
NEUROLOGY (2000)
Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome
I Reuter et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2000)
Structure and function of dopamine receptors
D Vallone et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2000)
The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease
M Glass et al.
NEUROSCIENCE (2000)
分享论文
